Next Article in Journal
High Resolution Melting (HRM) for High-Throughput Genotyping—Limitations and Caveats in Practical Case Studies
Previous Article in Journal
Divalent Cations Regulate the Ion Conductance Properties of Diverse Classes of Aquaporins
Article Menu
Issue 11 (November) cover image

Export Article

Open AccessArticle
Int. J. Mol. Sci. 2017, 18(11), 2326;

Whole Blood mRNA Expression-Based Prognosis of Metastatic Renal Cell Carcinoma

Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Biomarker Discovery, Center for Individualized Medicine, Mayo Clinic, Rochester, MN 55905, USA
Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA
Department of Oncology, Clínica Santa María, Santiago 8320000, Chile
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Received: 5 October 2017 / Revised: 28 October 2017 / Accepted: 31 October 2017 / Published: 3 November 2017
(This article belongs to the Section Molecular Pathology, Diagnostics, and Therapeutics)
PDF [1068 KB, uploaded 4 November 2017]


The Memorial Sloan Kettering Cancer Center (MSKCC) prognostic score is based on clinical parameters. We analyzed whole blood mRNA expression in metastatic clear cell renal cell carcinoma (mCCRCC) patients and compared it to the MSKCC score for predicting overall survival. In a discovery set of 19 patients with mRCC, we performed whole transcriptome RNA sequencing and selected eighteen candidate genes for further evaluation based on associations with overall survival and statistical significance. In an independent validation of set of 47 patients with mCCRCC, transcript expression of the 18 candidate genes were quantified using a customized NanoString probeset. Cox regression multivariate analysis confirmed that two of the candidate genes were significantly associated with overall survival. Higher expression of BAG1 [hazard ratio (HR) of 0.14, p < 0.0001, 95% confidence interval (CI) 0.04–0.36] and NOP56 (HR 0.13, p < 0.0001, 95% CI 0.05–0.34) were associated with better prognosis. A prognostic model incorporating expression of BAG1 and NOP56 into the MSKCC score improved prognostication significantly over a model using the MSKCC prognostic score only (p < 0.0001). Prognostic value of using whole blood mRNA gene profiling in mCCRCC is feasible and should be prospectively confirmed in larger studies. View Full-Text
Keywords: metastatic renal cell carcinoma; prognostic biomarkers; whole blood mRNA gene expression metastatic renal cell carcinoma; prognostic biomarkers; whole blood mRNA gene expression

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material


Share & Cite This Article

MDPI and ACS Style

Giridhar, K.V.; Sosa, C.P.; Hillman, D.W.; Sanhueza, C.; Dalpiaz, C.L.; Costello, B.A.; Quevedo, F.J.; Pitot, H.C.; Dronca, R.S.; Ertz, D.; Cheville, J.C.; Donkena, K.V.; Kohli, M. Whole Blood mRNA Expression-Based Prognosis of Metastatic Renal Cell Carcinoma. Int. J. Mol. Sci. 2017, 18, 2326.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top